Development of standardized cell culture conditions for tumor cells with potential clinical application

References

• Dillman RO, Beutel L, Nayak S, et al. Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes?. Cancer Biother Radiopharm 2005; 20: 373–8
   PubMedGoogle Scholar
• Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11: 4469–78
   PubMed Web of Science ®Google Scholar
• Zhou X, Jun do Y, Thomas AM, et al. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte–macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res 2005; 65: 1079–88
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70
   PubMed Web of Science ®Google Scholar
• Masters JRW. Human Cancer in Primary Culture. Kluwer Academic Publishers, Dortrecht 1991
   Google Scholar
• Freshney RI. Culture of Animal Cells. John Wiley & Sons, Hoboken 2005
   Google Scholar
• Iwamura T, Hollingsworth MA. Pancreatic tumors. Human Cell Culture: Cancer Cell Lines Part 1, JRW Masters, B Palsson. Kluwer Academic Publishers, Dordrecht 1999; 107–22
   Google Scholar
• Carney DN, Bunn PA, Gazdar AF, et al. Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc Natl Acad Sci USA 1981; 78: 3185–9
   PubMed Web of Science ®Google Scholar
• Pfragner R, Hofler H, Behmel A, et al. Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res 1990; 50: 4160–6
   PubMedGoogle Scholar
• Pfragner R, Wirnsberger G, Behmel A, et al. New continuous cell line from medullary thyroid carcinoma: SINJ. Phenotypic analysis and in vivo carcinogenesis. Int J Cancer 1993; 2: 831–36
   Google Scholar
• Pfragner R, Wirnsberger GH, Ingolic E, et al. Medullary thyroid carcinomas in cell culture: models for future therapies. Wien Klin Wochenschr 2002; 114: 279–83
   PubMedGoogle Scholar
• Steindl, F. General cell screening system: a new dimension in screening and cell culture, fermentation and cell culture/application note. Int Biotech Lab News Edn 1990:14.
   Google Scholar
• Kaczirek K, Schindl M, Weinhausel A, et al. Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J Clin Endocrinol Metab 2004; 89: 2397–401
   PubMedGoogle Scholar
• Vorauer K, Steindl F, Jungbauer A, et al. Cytokine activity assay by means of proliferation measured in plane convex microtiter wells. J Biochem Biophys Methods 1996; 32: 85–96
   PubMedGoogle Scholar
• Ganne V, Mignot G. Application of statistical design of experiments to the optimization of factor VIII expression by CHO cells. Cytotechnology 1991; 6: 233–40
   PubMedGoogle Scholar
• Terada S, Nishimura T, Sasaki M, et al. Sericin, a protein derived from silkworms, accelerates the proliferation of several mammalian cell lines including a hybridoma. Cytotechnology 2002; 40: 3–12
   PubMed Web of Science ®Google Scholar
• Tischler AS, DeLellis RA, Goltzman D, et al. Medullary carcinoma of the human thyroid in monolayer culture: morphological and cytochemical correlations. Cancer 1977; 40: 3004–13
   PubMedGoogle Scholar
• Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996; 67: 644–7
   PubMed Web of Science ®Google Scholar
• Blaker M, Arrenberg P, Stange I, et al. The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT. Regul Pept 2004; 118: 111–7
   PubMedGoogle Scholar
• Blaker M, de Weerth A, Tometten M, et al. Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma. Eur J Endocrinol 2002; 146: 89–96
   PubMedGoogle Scholar
• Maeda A, Akimoto M, Goto Y, et al. Reciprocal effect of unsulfated and sulfated forms of cholecystokinin-octapeptide on gastric acid secretion in the rat. Pharmacol Res 2000; 42: 333–6
   PubMedGoogle Scholar
• Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57: 1377–86
   PubMed Web of Science ®Google Scholar
• Moley JF. Medullary thyroid carcinoma. Curr Treat Options Oncol 2003; 4: 339–47
   PubMedGoogle Scholar
• Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658–71
   PubMed Web of Science ®Google Scholar
• Gagel RF, Goepfert H, Callender DL. Changing concepts in the pathogenesis and management of thyroid carcinoma. CA Cancer J Clin 1996; 46: 261–83
   PubMedGoogle Scholar
• Zitvogel L, Angevin E, Tursz T. Dendritic cell-based immunotherapy of cancer. Ann Oncol 2000; 11: 199–205
   PubMed Web of Science ®Google Scholar
• Schott M, Seissler J. Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies. Trends Endocrinol Metab 2003; 14: 156–62
   PubMed Web of Science ®Google Scholar
• Schott M, Feldkamp J, Klucken M, et al. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 2002; 51: 663–8
   PubMedGoogle Scholar
• Stift A, Sachet M, Yagubian R, et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 2004; 10: 2944–53
   PubMed Web of Science ®Google Scholar
• Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003; 21: 135–42
   PubMed Web of Science ®Google Scholar
• Pfragner R, Skofitsch G, Hoger H, et al. Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination. Anticancer Res 2005; 25: 4225–30
   PubMed Web of Science ®Google Scholar
• Collodi P, Rawson C, Barnes D. Serum-free culture of carcinoma cell lines. Cytotechnology 1991; 5: 31–46
   PubMedGoogle Scholar
• van der Bosch J, Masui H, Sato G. Growth characteristics of primary tissue cultures from heterotransplanted human colorectal carcinomas in serum-free medium. Cancer Res 1981; 41: 611–8
   PubMedGoogle Scholar
• Tsai CM, Perng RP, Chang KT, et al. Evaluation of the relative cytotoxic effects of anticancer agents in serum-supplemented versus serum-free media using a tetrazolium colorimetric assay. Jpn J Cancer Res 1996; 87: 91–7
   PubMedGoogle Scholar
• Leong SS, Horoszewicz JS, Shimaoka K, . A new cell line for study of human medullary thyroid carcinoma. Advances in Thyroid Neoplasia, M Andrejoli, F Manaco, J Robbins, et al. Field Edicational Italia, Rome 1981; 95–108
   Google Scholar
• Loo G. Redox-sensitive mechanisms of phytochemical-mediated inhibition of cancer cell proliferation (review). J Nutr Biochem 2003; 14: 64–73
   PubMed Web of Science ®Google Scholar
• Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 1999; 4: 304–29
   PubMedGoogle Scholar
• Barroso MP, Gomez-Diaz C, Lopez-Lluch G, et al. Ascorbate and alpha-tocopherol prevent apoptosis induced by serum removal independent of Bcl-2. Arch Biochem Biophys 1997; 343: 243–8
   PubMed Web of Science ®Google Scholar